71 search results
A021806: A Phase III Trial of Perioperative versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer
Location: Lebanon, St. Johnsbury, VT
Engagement of Rural Breast Cancer Survivors using Ecological Momentary Assessment Methods: A Feasibility Study
Location: Keene, Manchester, Nashua, Southwestern Vermont Medical Center, St. Johnsbury, VT
Immune profiling for cancer immunotherapy response
Location: Lebanon, St. Johnsbury, VT
NRG-HN010 : A Controlled, Randomized Phase II Trial of Docetaxel Plus Trastuzumab Versus Ado-Trastuzumab Emtansine for Recurrent, Metastatic, or Treatment-Naïve, Unresectable HER2-Positive Salivary Gland Cancer
Location: Lebanon, St. Johnsbury, VT
Anus
22BRO873 : Adaptive, individualized dosing of 5-fluorouracil-based chemotherapy to improve treatment efficacy while minimizing severe toxicity: Development and evaluation of the FOX regimen
Location: Lebanon, St. Johnsbury, VT
A Randomized Phase II Study of De-lntensified ChemoRadiation for Early Stage Anal Squamous Cell Carcinoma (DECREASE)
Location: Lebanon, St. Johnsbury, VT
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
Bones and Joints
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
Brain and Nervous System
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
Breast
A Phase III, Randomized, Single Blind, Attention Controlled, Multi-Center Study Of The Effects Of A Rehabilitation Intervention On Participation Restrictions Of Female Breast Cancer Survivors
Location: St. Johnsbury, VT
CCTG MA.39 - Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive and T3N0 Breast Cancer
Location: Lebanon, St. Johnsbury, VT
NRG-BR007: A Phase III Clinical Trial Evaluating DE-escalation of Breast RAdiation (DEBRA) for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score [less than or equal to] 18 Breast Cancer
Location: Lebanon, St. Johnsbury, VT
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
Cervix
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
Colon
22BRO873 : Adaptive, individualized dosing of 5-fluorouracil-based chemotherapy to improve treatment efficacy while minimizing severe toxicity: Development and evaluation of the FOX regimen
Location: Lebanon, St. Johnsbury, VT
Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer
Location: Lebanon, St. Johnsbury, VT
NRG-GI008 : Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)
Location: Lebanon, St. Johnsbury, VT
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
S2107 : Randomized Phase II trial of encorafenib and cetuximab with or without nivolumab (NSC #748726) for patients with previously treated, micorsatellite stable, BRAFV600E metastatic and/or unresectable colorectal cancer.
Location: Lebanon, St. Johnsbury, VT
Corpus Uteri
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
Esophagus
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
Eye and Orbit
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
Hodgkin Lymphoma
A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission
Location: Lebanon, St. Johnsbury, VT
Kaposi's Sarcoma
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
Kidney
S1931 Phase III Trial of Immunotherapy-Based Combination Therapy with or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial)
Location: Lebanon, St. Johnsbury, VT
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
Larynx
NRG-HN009 : Randomized Phase II/III Trial of Radiation with High-Dose Cisplatin (100 mg/m2) Every Three Weeks versus Radiation with Low-Dose Weekly Cisplatin (40 mg/m2) for Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck
Location: Lebanon, St. Johnsbury, VT
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
Lip - Oral Cavity and Pharynx
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
Liver
22BRO873 : Adaptive, individualized dosing of 5-fluorouracil-based chemotherapy to improve treatment efficacy while minimizing severe toxicity: Development and evaluation of the FOX regimen
Location: Lebanon, St. Johnsbury, VT
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
Lung
A211901:Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions
Location: Lebanon, St. Johnsbury, VT
NRG-LU007 Randomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC:RAPTOR trial
Location: Lebanon, St. Johnsbury, VT
NRG-LU008: Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy followed by Concurrent Mediastinal Chemoradiation for locally Advanced Non-Small Cell Lung Cancer
Location: Lebanon, St. Johnsbury, VT
S2302: PRAGMATICA - LUNG: A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) plus Pembrolizumab (MK-3475; NSC 776864) versus Standard of Care for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cel
Location: Lebanon, St. Johnsbury, VT
Melanoma - Skin
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
Multiple Myeloma
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
Non-Hodgkin's Lymphoma
A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission
Location: Lebanon, St. Johnsbury, VT
Other Digestive Organ
22BRO873 : Adaptive, individualized dosing of 5-fluorouracil-based chemotherapy to improve treatment efficacy while minimizing severe toxicity: Development and evaluation of the FOX regimen
Location: Lebanon, St. Johnsbury, VT
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
Other Endocrine System
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
Other Female Genital
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
Other Hematopoietic
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
Other Male Genital
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
Other Respiratory and Intrathoracic Organs
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
Other Skin
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
Other Urinary
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
Ovary
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
Pancreas
22BRO873 : Adaptive, individualized dosing of 5-fluorouracil-based chemotherapy to improve treatment efficacy while minimizing severe toxicity: Development and evaluation of the FOX regimen
Location: Lebanon, St. Johnsbury, VT
EA2192 : A Randomized Phase II Double-Blind Study of Olaparib versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Location: Lebanon, St. Johnsbury, VT
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
S2104: Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
Location: Lebanon, St. Johnsbury, VT
Prostate
A Randomized Phase II Study of De-lntensified ChemoRadiation for Early Stage Anal Squamous Cell Carcinoma (DECREASE)
Location: Lebanon, St. Johnsbury, VT
NRG-GU009: Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT*)
Location: Lebanon, St. Johnsbury, VT
NRG-GU010 Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification And Intensification Clinical Trial Evaluation (GUIDANCE)
Location: Lebanon, St. Johnsbury, VT
NRG-GU011 : A Phase II Double-Blind, Placebo Controlled Trial of Prostate Oligometastatic Radiotherapy with or without Androgen Deprivation Therapy in Oligometastatic Prostate Cancer (NEO PROMETHEAN)
Location: Lebanon, St. Johnsbury, VT
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
Rectum
22BRO873 : Adaptive, individualized dosing of 5-fluorouracil-based chemotherapy to improve treatment efficacy while minimizing severe toxicity: Development and evaluation of the FOX regimen
Location: Lebanon, St. Johnsbury, VT
Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer
Location: Lebanon, St. Johnsbury, VT
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
S2107 : Randomized Phase II trial of encorafenib and cetuximab with or without nivolumab (NSC #748726) for patients with previously treated, micorsatellite stable, BRAFV600E metastatic and/or unresectable colorectal cancer.
Location: Lebanon, St. Johnsbury, VT
Small Intestine
22BRO873 : Adaptive, individualized dosing of 5-fluorouracil-based chemotherapy to improve treatment efficacy while minimizing severe toxicity: Development and evaluation of the FOX regimen
Location: Lebanon, St. Johnsbury, VT
S1922: Randomized Phase II Selection Study of Ramucirumab and Paclitaxel Versus FOLFIRI in Refractory Small Bowel Adenocarcinoma
Location: Lebanon, St. Johnsbury, VT
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
Soft Tissue
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
Stomach
22BRO873 : Adaptive, individualized dosing of 5-fluorouracil-based chemotherapy to improve treatment efficacy while minimizing severe toxicity: Development and evaluation of the FOX regimen
Location: Lebanon, St. Johnsbury, VT
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
Thyroid
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
Urinary Bladder
A Randomized Phase II Study of De-lntensified ChemoRadiation for Early Stage Anal Squamous Cell Carcinoma (DECREASE)
Location: Lebanon, St. Johnsbury, VT
Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer
Location: St. Johnsbury, VT
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT